The new results, which were issued in a press release, could help shore up the perception that the medicine is effective. They also could boost hopes for the use of oral antiviral drugs being developed by drug companies including Pfizer and Merck to treat people in the early stages of Covid-19.

The administration of remdesivir remains challenging. It must be given intravenously, and in the study it was given in three infusions over three days — a logistical hurdle for patients who are not hospitalized.

Read more...